Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. (ACRX) on July 27, 2022. The report addresses the status of the Company's listing on The Nasdaq Global Market following a failure to meet the minimum bid price requirement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Listing Status
- Initial Notice: On December 2, 2021, Nasdaq notified the Company of non-compliance with Listing Rule 5450(a)(1) due to a closing bid price below $1.00 for 30 consecutive business days.
- Failure to Regain Compliance: On June 1, 2022, Nasdaq notified the Company of its failure to regain compliance within the initial 180-day period, subjecting the stock to delisting.
- Appeal Outcome: On July 27, 2022, the Nasdaq Hearings Panel granted the Company an extension to regain compliance.
- Compliance Deadline: The Company must demonstrate a closing bid price of $1.00 or more for 10 consecutive trading sessions on or before November 28, 2022.
Outlook, Management Commentary, and Risks
Management intends to regain compliance within the extended period, potentially utilizing a reverse stock split if necessary. The Company plans to actively monitor its closing bid price and evaluate available options. The primary risk is that failure to meet the $1.00 bid price requirement by November 28, 2022, will result in a final delisting determination and suspension of trading on The Nasdaq Global Market. The Panel noted this extension represents the full extent of its discretion.
Investor Verification Checklist
- Verify the current closing bid price of ACRX common stock relative to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split to achieve compliance.
- Track the stock's performance leading up to the November 28, 2022, deadline to assess delisting risk.
- Review subsequent filings for updates on the Company's compliance status or further appeals.